Teva Pharmaceuticals, Inc.

Hatch-Waxman ANDA litigation brought by Array BioPharma against Teva over Teva's generic binimetinib 15 mg tablets (ANDA No. 217509). The case ended in a stipulated dismissal/settlement after briefing on Teva's stay motion pending appeal of the crystallized binimetinib claim construction from the Alembic/Sandoz litigation. Although U.S. 9,314,464 appeared on the case's USPTO report, the narrative states Array asserted only the three Crystallized Binimetinib Patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva, and Teva's Paragraph IV notice did not address the '464 patent.